Abstract-Angiotensin II (Ang II), acting through its G protein-coupled AT 1 receptor (AT 1 ), contributes to the precocious heart senescence typical of patients with hypertension, atherosclerosis, and diabetes. AT 1 was suggested to transactivate an intracellular signaling controlled by growth factors and their tyrosin-kinase receptors. In cultured vascular smooth muscle cells, this downstream mechanism comprises the p66 Shc adaptor protein, previously recognized to play a role in vascular cell senescence and death. The aim of the present study was 2-fold: (1) 
xaggerated activation of the renin-angiotensin system accelerates cardiac senescence, a process consisting of cardiomyocyte hypertrophy and loss, capillary rarefaction, replacement fibrosis, and ventricular remodeling. Ang II produces its multiple actions by activating the G proteincoupled 7 transmembrane domain (7-TMD) AT 1 and AT 2 receptors (AT 1 and AT 2 ). AT 1 mediates vasoconstriction, vascular smooth muscle cell (VSMC) proliferation, cardiomyocyte hypertrophy, apoptosis, and fibrosis. AT 1 is also involved in oxidative stress. 1 Beside its notorious G protein-mediated effects, in cultured VSMCs, AT 1 was shown to transactivate a pathway downstream of the tyrosin-kinase receptors for epidermal growth factor (EGF) and platelet-derived growth factors (PDGFs) and including the Shc adaptor protein. 2, 3 Shc exists in 3 isoforms with relative molecular masses of 46, 52, and 66 kDa (p46 Shc 
, p52
Shc , and p66 Shc ). The 3 isoforms share an Src-homology2 (SH2) domain, a collagen-homology (CH1) region, and a phosphotyrosine-binding (PTB) domain.
P46
Shc and p52 Shc arise from the use of alternative translation initiation sites within the same transcript, whereas p66
Shc contains a unique N-terminal region and is generated as a result of alternative splicing. Shc is tyrosine-phosphorylated in response to growth factors and Ang II. Once phosphorylated, Shc forms a complex with Grb2, 4, 5 recruiting the Son-of-sevenless (SOS) exchange protein to the plasma membrane for activation of Ras. 6 Recent studies have suggested distinct physiological roles for the 3 Shc isoforms. In particular, whereas both p46 Shc and p52
Shc promote cell proliferation and differentiation via Ras and MAP kinases, 6 p66
Shc was proposed as a key factor controlling aging-related processes. 6, 7 In fact, some of the authors of the present study demonstrated that p66
Shc knockout mice (p66 ShcϪ/Ϫ ) exhibit enhanced cellular resistance to oxidative stress and a 30% increase in life span. 7 In this study, we investigated whether p66 Shc is implicated in the damaging effects elicited by Ang II on the heart. To this aim, the cardiovascular phenotype of p66 ShcϪ/Ϫ was characterized under basal conditions and after chronic infusion with a sub-pressor dose of Ang II. Wild-type littermates (p66 Shcϩ/ϩ ) served as controls. In addition, an in vitro apoptosis test was performed on adult p66 ShcϪ/Ϫ and p66 Shcϩ/ϩ cardiomyocytes that were stimulated with escalating concentrations of Ang II.
Our results document for the first time that p66 Shc disruption combats Ang II-induced myocardial hypertrophy and protects cardiomyocytes and endothelial cells from apoptosis.
Moreover, in p66
ShcϪ/Ϫ , the number of cycling cardiomyocytes was higher under basal conditions and after Ang II.
Altogether, our findings open new avenues for mechanistic interventions targeting specific molecular pathways of Ang II-induced myocardial damage.
Materials and Methods

p66
ShcϪ/Ϫ were generated from a 129 Sv background. 7 p66
ShcϪ/Ϫ littermates (p66 Shcϩ/ϩ ) served as wild-type controls. Experiments were performed on male mice aged 3 to 5 months.
Details of experimental procedures are provided in the Expanded Methods Online Supplement.
In Vivo Experimental Protocol
The body weight (BW), systolic blood pressure (SBP), and heart rate (HR) of p66 ShcϪ/Ϫ (nϭ21) and p66 Shcϩ/ϩ (nϭ18) were determined under basal conditions.
After completion of basal measurements, p66 ShcϪ/Ϫ and p66 Shcϩ/ϩ were randomized to receive a chronic infusion of Ang II at sub-pressor dosage (300 nmol/kg BW, IP daily for 28 days, nϭ10 for each strain) or saline (vehicle, nϭ11 p66 ShcϪ/Ϫ and nϭ8 p66 Shcϩ/ϩ ). BW, SBP, and HR were recorded at weekly intervals. Intra-arterial mean blood pressure (MBP) was measured at 28 days.
Heart Histology
After final MBP measurements, hearts of anesthetized mice were arrested in diastole and fixed. Left ventricle (LV) weight (LVW) and right ventricle weight (RVW) were recorded and corrected to the BW. The following parameters were determined: LV transverse diameter, LV free wall thickness, RV wall thickness, LV chamber volume. Transverse LV slices were embedded in paraffin for subsequent histological or immunohistochemical analyses.
Cardiomyocyte transverse diameter and myocardial capillary density were determined in LV sections.
Putative cardiac progenitor cells (CPCs) were identified as those cells expressing both the stem cell marker c-Kit and the cardiac transcription factor GATA-4. 8 The density of c-kitϩ/GATA-4ϩ CPCs per mm 3 of myocardium was determined. We also calculated the CPC number every 1000 myocardial cells. Cycle-active cells were recognized by staining for the minichromosome maintenance protein-2 (MCM-2). 9 MCM proteins, inducible by the E2F transcription factors, 10 are currently used as cell-cycling markers. 9 The MCM-2-positivity of CPCs and cardiomyocytes (recognized by ␣-sarcomeric actin staining) was differentially calculated and used as an index of cellular cycling for the 2 cardiac populations. Proliferating endothelial cells (ECs) were recognized by double staining for MCM-2 and the EC marker Factor VIII.
Adult Cardiomyocyte Dimensions and Number
The dimensions of cardiomyocytes isolated from untreated p66 Shcϩ/ϩ (nϭ15) and p66
ShcϪ/Ϫ (nϭ24) were determined. The aggregate number of myocytes in the heart was calculated by combining measurements obtained by the in situ analysis of the myocardium with the estimation of the volume of isolated myocytes.
Additionally, we measured the transverse diameter of myocytes in LV sections from saline-and Ang II-treated p66
Shcϩ/ϩ and p66 ShcϪ/Ϫ hearts.
Myocardial Apoptosis
Apoptotic cardiomyocytes and ECs were recognized in LV sections by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining assay. Cardiomyocytes and ECs were identified for their morphology and for being positive to ␣-sarcomeric actin or Factor VIII, respectively. The number of apoptotic cardiomyocytes and apoptotic ECs per square millimeter section was calculated. 
In Vitro Ang II-Induced Apoptosis
Expression of Shc Isoforms in the Hearts
P66
Shcϩ/ϩ or p66 ShcϪ/Ϫ received saline or Ang II for 22 days (nϭ5 mice per each group). The contents of the 3 shc isoforms in heart homogenates were determined by Western blot. P46
Shc and p52 Shc levels were also determined in cardiomyocytes harvested from untreated mice of both strains.
Statistics
Results were expressed as meanϮSEM. Multivariate repeated-measures ANOVA was performed. In multiple comparisons in which ANOVA indicated significant differences, the statistical value was determined according to Bonferroni. Differences within and between groups were determined using paired or unpaired Student t test, respectively. A P value Ͻ0.05 was interpreted to denote statistical significance.
Results
Basal Cardiovascular Phenotype of p66
Shc؊/؊ As shown in Table 1 , under basal conditions, no difference was recorded between strains in terms of BW, SBP, or HR.
The impact of p66 Shc gene deletion on cardiac phenotype was evaluated in more detail at the end of a 4-week infusion with saline or Ang II.
As shown in The cardiac phenotype of the two strains was differentially modified by chronic infusion of Ang II. As shown in Table  2 , Ang II did not change tail-cuff SBP or HR or intraarterial MBP in either strain. However, profound differences were observed in heart histomorphology. As shown in Table 2 and Figure 1 , Ang II-infused p66 Shcϩ/ϩ displayed LV hypertrophic remodeling (as denoted by the 1.11-fold increase in cardiomyocyte transverse diameter, 1.23-fold increase in LVW/BW, and 1.49-fold reduced cavitary volume, PϽ0.05 versus saline-infused for all comparisons). In contrast, in p66 ShcϪ/Ϫ , Ang II neither produced myocyte hypertrophy nor altered the LVW/BW and LV cavitary volume (PϭN.S. versus saline infusion for all comparisons).
After Ang II, myocardial capillary density decreased without difference between strains. Thus, deletion of p66 Shc preserves the heart from Ang II-induced hypertrophic remodeling, but it does not avoid cardiac capillary rarefaction.
Resistance of p66
Shc؊/؊ Hearts to Ang
II-Induced Apoptosis
As shown in Figure 2A , the number of TUNELϩ cardiomyocytes was similar in saline-infused p66 Shcϩ/ϩ or p66 ShcϪ/Ϫ . Apoptosis was strikingly enhanced by Ang II in p66 Shcϩ/ϩ , but it remained at low levels in p66 ShcϪ/Ϫ . Microphotographs in Figure 2B show greater abundance of apoptotic cardiomyocytes (indicated by arrows) in LV sections from Ang IIinfused p66
Shcϩ/ϩ as compared with p66 ShcϪ/Ϫ . 
Cycling Cardiomyocytes Are More Abundant in p66
Shc؊/؊
In the LV of saline-infused p66 Shcϩ/ϩ , a small fraction of cardiomyocytes was MCM-2ϩ (circa 0.2% of total), and this figure was doubled in p66
ShcϪ/Ϫ ( Figure 2C ). As shown by Figure 2A and 2C, the number of MCM-2ϩ cardiomyocytes and TUNELϩ cardiomyocytes was similar in saline-infused p66 Shcϩ/ϩ . At variance, in saline-infused p66 ShcϪ/Ϫ , MCM-2ϩ cardiomyocytes numerically exceeded TUNELϩ cardiomyocytes. Ang II increased the number of cycling cardiomyocytes in both strains. Nevertheless, in p66 Shcϩ/ϩ , apoptosis exceeded proliferation, whereas the opposite figure was observed in p66 ShcϪ/Ϫ . Figure 2D shows 2 cells in active cell cycling, as revealed by the nuclear expression of MCM-2 (green fluorescent dots) in the LV of Ang II-infused p66 ShcϪ/Ϫ . One of these cells is a small myocyte, as indicated by its expression of ␣-sarcomeric actin (in red fluorescence). Nuclei are counterstained in blue.
Altogether, the above results indicate that, in p66 Shcϩ/ϩ , Ang II triggers cardiomyocyte hypertrophy and apoptosis over- whelming concurrent cell cycling. Interestingly, the heart of mice lacking the p66 Shc gene is protected from Ang IIinduced hypertrophy and apoptosis and enriched with cycling cardiomyocytes.
Isolated Cardiomyocytes
In vitro experiments were conducted to exclude the interference of hemodynamic factors, completely. As shown by Figure 3A , the rate of spontaneous cardiomyocyte apoptosis was similar in the 2 strains. Ang II at 10 
Cardiac Progenitor Cells
CPCs might be implicated in myocardial plasticity. Therefore, we explored whether p66 Shc deletion influences the relative abundance and cycling rate of CPCs in the adult heart.
As shown in Figure 4A and 4B, after saline infusion, the relative abundance of c-kitϩ/GATA-4ϩ putative CPCs was similar in p66
Shcϩ/ϩ and p66 ShcϪ/Ϫ . However, a strain difference was observed with regard to CPC response to Ang II. In fact, Ang II augmented CPC density in p66
Shcϩ/ϩ , but not in p66
ShcϪ/Ϫ . The difference is compatible either with a stimulatory action of Ang II on CPCs through p66 Shc or with a compensatory activation of CPCs aimed at counteracting the Ang II-induced myocyte loss. Figure 4C shows a LV section from Ang II-infused p66 Shcϩ/ϩ , where a CPC (white arrow) is identified by its double positivity for c-kit (green fluorescence) and GATA-4 (magenta fluorescent dots in the nucleus) and cardiac myocytes are recognized by their expression of ␣-sarcomeric actin (red fluorescence). Because of CPC scarcity in the heart, this picture is not representative of the actual CPC density.
As shown by Figure 4D , the percentage of MCM-2ϩ CPCs was higher in saline-treated p66
ShcϪ/Ϫ than in p66 Shcϩ/ϩ . Ang II did not affect CPC cycling in any strain. Assuming the CPC proliferation rate to be constant through all the infusion period, the latter finding indirectly suggests that CPC numerical increment in p66 Shcϩ/ϩ may be attributable to differentiation from more immature cardiac stem cells 11 rather than to CPC proliferation.
Myocardium Capillary Density and Turnover of Cardiac ECs
As shown in Figure 5A , p66 ShcϪ/Ϫ hearts were also protected from Ang II-induced EC apoptosis. Figure 5B shows images of LV sections from Ang II-infused p66
Shcϩ/ϩ and p66 ShcϪ/Ϫ . Apoptotic ECs (indicated by the arrows) can be recognized by concomitant positivity for TUNEL (dark brown) and Factor VIII (purple).
As shown in Figure 5C , under saline infusion, the number of MCM-2ϩ ECs was higher in p66
ShcϪ/Ϫ than in p66 Shcϩ/ϩ . 
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However, capillary density was similar in the 2 strains ( Figure 5D ). As shown in Table 2 and Figure 5D , Ang II similarly reduced cardiac capillary density in p66
Shcϩ/ϩ and p66 ShcϪ/Ϫ . We hypothesize that p66
Shc controls EC proliferation under physiological levels of Ang II, while facilitating EC death as triggered by exaggerated Ang II.
Shc Isoforms
We then evaluated the possibility that p46
Shc and p52
Shc expression may be affected by p66 Shc knock-out. As shown in the representative Western blot bands of Figure 6 , the cardiac expression levels of p46 Shc 12 Here, we show that p66
ShcϪ/Ϫ display a normal basal phenotype with regards to BW, systemic hemodynamics, and left ventricular wall thickness. CPC density was also similar in the two strains. At variance with what reported for the limb skeletal muscle, 13 myocardial capillary density was normal in p66 ShcϪ/Ϫ . However, there were also peculiar differences that could be related to the mutation. In particular, the number of cardiomyocytes and the cycling index of both cardiomyocytes and CPCs were all increased in p66 ShcϪ/Ϫ . This was associated with a reduced LV chamber volume in mutant animals. The combination of these characteristics is compatible with a condition of myocardial hyperplasia. We hypothesize that these features may derive from increased cell proliferation together with reduced apoptosis during the development of p66 ShcϪ/Ϫ hearts. We know from the literature that apoptosis participates in the intrauterus and early postgestational heart development 14, 15 and that all the components of the renin-angiotensin system are expressed by the fetal heart and participate in its normal development. 16, 17 Interestingly, a recent study from a coauthor of this article showed that the 3 Shc isoforms are activated in the human fetal heart, in a period that is characterized by apoptotic and proliferative processes. 15 In our opinion, the p66 Shc knock-out may interfere with the heart development by inhibiting the apoptotic and hypertrophic signaling emanating from AT 1 or other factors as well as enhancing the proliferation of cardiomyocyte and CPCs.
The major objective of this study was to ascertain whether p66
Shc modulates the cardiac effects of moderate increments of circulating Ang II. A large body of evidence supports the notion that Ang II, independently of its blood pressureelevating effect, plays a central role in the pathophysiology of heart remodeling and failure. The underlying molecular mechanisms are complex and not yet completely clarified. Here, we report for the first time that Ang II produces damaging effects on the heart through a p66
Shc -comprising pathway. Circumstantial evidence suggests that activation of the p66
Shc , which lays downstream to tyrosin kinase receptors, may be implicated in Ang II-induced cardiovascular alterations. For instance, 2 studies showed increased p66 Shc expression in Ang II-stimulated VSMCs. 18, 19 Using genetically modified mice, we specifically challenged the hypothesis that p66
Shc participates in the cascade leading to Ang II-induced ventricular remodeling. To eliminate the confounding effects of hypertension, Ang II was chronically infused at a dose known to be devoid of pressor activity. Accordingly, systemic hemodynamics remained unchanged in both strains. Nevertheless, relevant differences were observed with regard to the cardiac effects of the agent: chronic Ang II caused myocardial hypertrophy and apoptosis in p66 Shcϩ/ϩ but not in p66 ShcϪ/Ϫ , thus suggesting a fundamental role of p66
Shc in Ang II-induced cardiac damage. Consistently, p66
ShcϪ/Ϫ were protected from apoptosis caused by limb ischemia, 13 high-fat diet, 20 and free radicals generating poisons. 7 However, p66
ShcϪ/Ϫ were not spared from Ang II-induced rarefaction of myocardial microcirculation. This fact is apparently difficult to reconcile with our own findings of reduced EC apoptosis in p66 ShcϪ/Ϫ . However, we also show that Ang II reduced the rate of spontaneous proliferation of myocardial ECs, particularly in p66 ShcϪ/Ϫ . Therefore, the capillary rarefaction in response to Ang II may derive from differential effects on ECs in the 2 strains.
Capillary destabilization in response to chronic Ang II is apparently discrepant with neo-angiogenesis which reportedly occurs in ischemic limb muscles of Ang II-infused animals. 21 One major difference, however, consists of the presence or absence of the hypoxic environment as a determinant of microvascular responses to Ang II. Another possible explanation deals with expressional and functional differences of vascular endothelium from different organs. 22 Whatever is the interpretation, microvascular factors are not accountable for the cardiac protection ensured by p66 Shc gene deletion.
In vitro experiments on adult cardiomyocytes definitively documented that Ang II-induced apoptosis is abrogated in the absence of p66
Shc . Similarly, primary cells (hematopoietic precursors, fibroblasts, and ECs) isolated from p66 ShcϪ/Ϫ are resistant to oxidative stress-induced apoptosis, whereas p66
Shc overexpression induces apoptosis in the same cells. 23 Ang II, via AT 1 receptors, upregulates the expression of a variety of redox-sensitive factors and NADPH oxidase, thus increasing the generation of reactive oxygen species (ROS) and cellular damage. 24 p66
Shc was initially shown to be involved in tyrosin-kinase receptor-initiated apoptosis. 25 Recent studies indicate that p66
Shc regulates apoptosis by controlling mitochondrial transmembrane potential and ROS production/accumulation. 12 Accordingly, p66 ShcϪ/Ϫ cells have reduced ROS under basal concentrations and after p53-induced apoptosis. Thus, it is possible that p66
Shc modulates Ang II-induced apoptosis via regulation of ROS. Furthermore, Ang II induces the expression of heat shock protein 70, 26 whose antiapoptotic action is constitutively inhibited when complexed with mitochondrial p66
Shc . Thus, another possibility is that the p66 ShcϪ/Ϫ may unveil the protective action of counter-regulatory mechanisms activated by Ang II.
Recent evidence suggests that the heart is not a postmitotic organ and that a continuous turnover of cardiac cells may result in a heterogeneous population of immature, adult, and senescent cardiomyocytes. 11 The contribution of resident cardiac stem cells and CPCs in physiological and pathological turnover of adult cardiomyocyte is also a matter of intense debate. Here, we report that Ang II stimulates the cycling of adult cardiomyocytes and increases the number of putative CPCs. These compensatory responses might not be sufficient to counteract ongoing cell loss by apoptosis in the p66 Shcϩ/ϩ hearts. p66
Shc deficiency did not affect the cycling of adult cardiomyocytes under Ang II stimulation, but it prevented the increase in c-kitϩ/GATA-4ϩ putative CPCs. These results may reflect the fact that in the absence of significant cardiomyocyte apoptosis there is no need for activation of compensatory responses. Alternatively, we might hypothesize a direct effect of p66 Shc in the control of cardiac cell maturation and turnover.
Perspectives
Our study newly demonstrates the involvement of p66
Shc in the deleterious cardiac responses to increased Ang II, namely hypertrophy of cardiomyocytes and LV and apoptotic death of cardiomyocytes and ECs. These results may have important clinical and therapeutic implications. It is possible that p66
Shc expression and activity differ between individuals, thus accounting for inter-individual variation in the susceptibility to Ang II-induced organ damage.
The present study also points to p66 Shc as a potential target to combat myocardial remodeling and senescence triggered by exaggerated Ang II. In perspective, p66
Shc inhibitors might protect from excessive apoptotic loss of cardiomyocytes, thereby delaying the onset of cardiac decompensation. 
Basal Hemodynamics.
After 3 training sessions, the systolic blood pressure (SBP) and heart rate (HR) of conscious mice were measured by plethysmography (Visitech System, USA) for 3 consecutive times at 72-hour intervals and then averaged. Anaesthetized adult mice were heparinezed (100 UI/kg BW, IP) and their hearts were rapidly excised and hanged in a Laghendorff apparatus.
Isolated cells were obtained by collagenase perfusion of the heart. 4 The procedure allows for a low degree of contamination from non-myocytes, that ranged from 1% to 3%.2x10 4 /cm 2 on laminin coated two-well chamber slides, cultured at 37°C
in an atmosphere containing 5% CO 2 for 48h in serum free medium, and then fixed in 4% PFA. Myocytes were stained with fluorescein isothiocyanate (1 µg/mL, for 30 min) to visualize the cell cytoplasm and with acridine orange (20 µM, for 1h) to label the nuclei. One hundred myocytes per heart were examined by confocal microscopy, considering the two cellular populations (mononucleated and binucleated myocytes).
The percentage and the dimension of mononucleated and binucleated myocytes were determined. [6] [7] [8] Myocytes dimensions were calculated by measuring the major and minor axis. In addition, myocyte thickness was determined by optical sectioning of each cell in the Z plane. 5 Cell volume was then calculated assuming an elliptical cross-section with a major axis that is equivalent to cell width and a minor diameter computed from the axis ratios, as previously reported. Cross-sectional area was multiplied by myocyte length to calculate myocyte volume.
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Calculation of the Total Number of Adult Cardiomyocytes.
The total volume of the myocardium was first determined by dividing its weight by the specific gravity of muscle tissue (1.06). 6, 8 Then, the volume fraction of myocytes and interstitium in each heart was determined in H&E-stained heart cross sections. 6, 8 The total volume of myocytes in the heart was then calculated from the product of heart volume and the volume fraction of myocytes. From the volume fraction of myocytes in the myocardium and the proportion of mononucleated Expanded Methods
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and binucleated cells, determined as described above, the volume percent of each cell population in the tissue was obtained. 6, 8 This information, combined with the total volume of myocytes in the heart, allowed the estimation of the aggregate volume of mononucleated and binucleated cells in the myocardium. 6, 8 The numbers of mononucleated and binucleated cells in the heart were computed from the quotient of their aggregate volumes and their corresponding average cell volume.
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Measurement of Cardiomyocyte Transverse Diameter in LV Sections.
In H&E-stained sections of the LV, the myocyte transverse diameter was determined (at 250X magnification) in the region of the nucleus of longitudinally oriented myocytes. Fifty measurements from each LV were averaged.
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Identification of Cardiomyocyte Progenitor Cells (CPCs) and
Identification of Cycling CPCs, Cardiomyocytes, and Endothelial
Cells (ECs).
To evaluate the presence of cardiac progenitor cells (CPCs), heart sections were first incubated with an antibody for the stem cell receptor factor c-kit (rabbit polyclonal antibody, 1: 20, Santa Cruz, pre MW treatment), which was revealed using a FITC-conjugated anti-rabbit Nuclei were visualized by bisbenzimide blue.
Evaluation of Apoptotic Cardiomyocytes and Apoptotic ECs in LV
Section.
LV sections (3 µm in thickness) were prepared onto poly-lysin coated slides for evaluation of DNA fragmentation by terminal 
